Halozyme Therapeutics, Inc. HALO

Key data

What the scoreboard pays for

Seventy percent of the cash rides on two figures the company defines itself. The revenue measure drops deals signed during the year and the milestone from amivantamab's first sale, putting the scoreboard $46.6 million under reported revenue. The profit measure excludes research bought in an acquisition. In the year Halozyme spent about $1.0B on Elektrofi and Surf Bio and charged $284.9 million of it off as acquired research, the scoreboard read $913 million and funded at the maximum. Shareholders were handed $657.6 million, because SEC guidance kept that charge in. The bonus definition took it out.

For 2026 the deal points bar moved. One hundred fifty percent now takes 19 points instead of 15, and the maximum takes 24 instead of 20.

What it has paid so far

The bars rose in real terms, the 2025 revenue bar of $1.2B sitting well above the $957.5 million done in 2024. Six goals became ten, financial weight fell from eighty percent to seventy, and the softer fifteen percent paid double on patents filed.

Every settled window paid something and seven of nine paid above target. Twice the share price fell across the window and shares were earned anyway, because the comparison set fell further. One row does not foot: the 2023 grant's three-year window is disclosed at the 43rd percentile with 122.89% earned, where the plan's own grid puts 86%.

Where it stands and what she does next

Capital is not the constraint. The cheapest way to move a price from $107.55 to $115 is to shrink the count, and that authority, running since February 2024, was renewed in May, five months after the price award was signed. Watch whether the $400 million floor becomes the ceiling, whether the deal count holds its August pace, and whether the next proxy still carves acquired research out of the bonus while the shareholder figure keeps it in.

What the plan cannot wish away is the capital structure. Every dollar above $136.78 is dilution the capped calls stop covering, and the 2027 notes at a $77.17 conversion price opened to holders on September 1 with $209.6 million due March 1. Reaching the top hurdle costs the company through the same instruments it bought protection with, the familiar trap of financing growth with converts and then succeeding.

Torley exercised 636,740 options in the twelve months to September 11, 2026, sold 508,492 shares for $39.8 million, and ended every one of those months holding exactly 767,780 shares. Nothing she owned outright went out the door, and her stake at the September price is a computed $82.6 million against a guideline of six times a $1,000,000 salary. Below her the tape is quiet, the only sale of owned stock in the window being a director's 13,330 shares for $989,847.

Closing thoughts

Halozyme pays its chief executive to grow revenue, to grow a profit number measured before the cost of the companies she buys, and now to put the share price at $115 and hold it. Two of those three are delivered, and the third sits about seven dollars away with a fresh billion dollars of repurchase authority behind it. What lands on the owner is the dilution above $136.78 the company already paid once to avoid.